You have free access to this content

Clinical Liver Disease

Cover image for Clinical Liver Disease

Edited By: Michael Lucey, MD

Online ISSN: 2046-2484

Associated Title(s): Hepatology, Liver Transplantation

Recently Published Issues

See all

  • Current Issue:October 2014

    Volume 4, Issue 4

    Special Issue: The Pediatric Liver Patient

  • September 2014

    Volume 4, Issue 3

    Special Issue: Liver Disease in Pregnancy

  • August 2014

    Volume 4, Issue 2

    Special Issue: Liver-Lung Syndromes

  • July 2014

    Volume 4, Issue 1

    Special Issue: Drug-Induced Liver Injury (DILI)

  • June 2014

    Volume 3, Issue 6

    Special Issue: Vascular Disorders

New Issue: The Pediatric Liver Patient

Binita Kamath, MD, MBBChir, MRCPGuest Edited by
Binita Kamath

MD, MBBChir, MRCP
The Hospital for Sick Children

Liver Disease in the Survivor with Congenital Heart Disease
Elizabeth B. Rand, MD
Figure 1
The impacts of liver disease in survivors of CHD are diverse - learn about the types, diagnostic modalities and management of liver disease that arises as a direct consequence of CHD.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Liver Disease in the Young Adult with Cystic Fibrosis
Deirdre Kelly, MD
Learn how the rapid development of new diagnostic tests, improved therapy, and especially the success of liver transplantation has changed the outcome for young adults with cystic fibrosis liver disease, many of whom now survive into adolescence and adult life.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



Management of Adult Survivors of Biliary Atresia
Simon C. Ling, MB, CHB
Surgical interventions now allow the majority of infants affected by BA to survive into adulthood, leading to a new population of patients - Dr. Simon Ling reviews the clinical status and management priorities for BA patients who survive to adulthood with their native liver.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME



NAFLD in the Transition From Adolescence to Young Adulthood
Miriam B. Vos, MD, MSPH
Figure 1
Learn about diagnosis, management, and other considerations for liver disease in adolescents after bariatric surgery.
Read the full textListen to the article presentationAnswer questions and earn CME

The Adult Survivor with Variceal Bleeding
Juan G. Abraldes, Puneeta Tandon, and Jason Yap
Portal hypertension complicated by variceal bleeding is a rare condition in young adults, but it is a frequent problem faced in transition clinics - read from the experts on what clinicians need to know.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

Series on New Treatments for Hepatitis C

Guest Edited by Donald M. Jensen, M.D., F.A.C.P.

NEW:

HCV Treatment of Special Populations:
HIV Coinfected, Liver Transplant, and Renal Failure

Nadeem Anwar, M.D., and Kenneth E. Sherman, M.D., Ph.D.
With new recommendations regarding birth cohort screening, more and more people will be diagnosed and referred for HCV treatment. Even in the new era of DAA therapy, some populations still require special consideration - learn more from Drs. Anwar and Sherman.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME


Check out other hot topics in CLD's sister journal, HEPATOLOGY

HEPATOLOGY Highlights


More recent articles on HCV:

HCV Testing and Linkage to Care:
Expanding Access

Nancy Reau, M.D.
The limitation to HCV therapy is not treatment efficacy; it's identification of patients and linking them to providers interested in delivering antiviral therapy. Where does the system break down? Dr. Nancy Reau investigates.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

Read Dr. Reau's recent editorial:
Reau NS, Jensen DM. Sticker shock and the price of new therapies for hepatitis C: Is it worth it? Hepatology. 59:4 1246–1249, April, 2014.

New All-Oral HCV Therapies for Genotype 1: A Final Good-bye to Interferon
Anna S.F. Lok, M.D.
With more than 30 direct-acting antiviral agents (DAAs) in clinical trials, the hepatitis C community anticipates that the right combinations of DAAs will emerge, permitting treatment of hepatitis C virus (HCV) genotype 1 with interferon (IFN)-free regimens.
Read the full textWatch the author interview.Listen to the article presentationAnswer questions and earn CME

For more information related to HCV genotypes, read:
Goossens N, Negro F. Is genotype 3 of hepatitis C virus the new villian? Hepatology. 59:6, 2403–2412, June 2014.



New AASLD/IDSA HCV Practice Guidelines: An Online Resource
Gary L. Davis, M.D.
As treatment for Hepatitis C rapidly evolves, how are recommendations being developed, and how they will be updated over time? Read or listen to Dr. Gary Davis' review to learn more about how organiziations like the AASLD are working to keep clinicians informed with the best and most up-to-date guidelines.
Read the full textListen to the article presentationAnswer questions and earn CME



Recent FDA Approval of Sofosbuvir and Simeprevir. Implications for Current HCV Treatment
M. Valerie Lin, M.D., and Raymond Chung, M.D.
Drs. Lin and Chung break down what clinicians need to know about Sofosbuvir and Simeprevir: from mechanisms of action, to approved indications, use outside approved indications, and treatment challenges.
Read the full textListen to the article presentationAnswer questions and earn CME

Connect with CLD

Find CLD on FacebookFollow CLD on TwitteriTunes

SEARCH

SEARCH BY CITATION